Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena's Lorcaserin Reaches FDA, But Without REMS Proposal

Executive Summary

Arena Pharmaceuticals filed the NDA for its obesity drug lorcaserin Dec. 22, crossing the top item off the firm's news flow list and refocusing attention on the drug's partnering potential in a shifting regulatory and competitive landscape

You may also be interested in...



Arena Gets Financing Boost, Lorcaserin Advisory Committee Date

Deerfield takes a $35.5 million equity stake, but finding a commercialization partner is still Arena's focus as it prepares for the September 16 panel review of its obesity drug.

Business News In Brief

Sandoz names DeGolyer head of U.S. business: Sandoz appointed Don DeGolyer President of its U.S. business unit, replacing Christine Mundkur who is leaving to pursue other opportunities, the drug maker announced March 8. Mundkur served a short role at the company after leaving her position as chief executive of Barr to shape up Sandoz's U.S. operation and grow the generics business in early 2009 (1"The Pink Sheet," Feb. 16, 2009). DeGolyer most recently held the position of senior VP and head of U.S. Commercial Operations for Sandoz US. At the same time, Sandoz also appoints Richard Tremonte VP of U.S. Retail Sales and Marketing, from his post as senior director of marketing for Sandoz U.S., which he held after joining the company in 2007

Business News In Brief

Sandoz names DeGolyer head of U.S. business: Sandoz appointed Don DeGolyer President of its U.S. business unit, replacing Christine Mundkur who is leaving to pursue other opportunities, the drug maker announced March 8. Mundkur served a short role at the company after leaving her position as chief executive of Barr to shape up Sandoz's U.S. operation and grow the generics business in early 2009 (1"The Pink Sheet," Feb. 16, 2009). DeGolyer most recently held the position of senior VP and head of U.S. Commercial Operations for Sandoz US. At the same time, Sandoz also appoints Richard Tremonte VP of U.S. Retail Sales and Marketing, from his post as senior director of marketing for Sandoz U.S., which he held after joining the company in 2007

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel